ArticleFrontiers in immunology2025
Safety and efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy: a retrospective cohort study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial: Innovative therapeutic approaches for complex cancers: exploring new strategies.Frontiers in immunology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a highly prevalent type of malignant tumor worldwide. Patients with locally advanced gastric cancer (LAGC) frequently have a poor prognosis due to the inability to achieve R0 resection. Neoadjuvant chemotherapy (NAC) can enhance survival rates, although its effectiveness is limited. Immune checkpoint inhibitors (ICIs) have demonstrated potential in treating advanced gastric cancer, but their efficacy in neoadjuvant therapy (NAT) for LAGC remains unclear. The aim of this study was to evaluate the safety, pathological response and survival outcome of neoadjuvant chemotherapy plus immunotherapy (NACI) versus NAC alone after laparoscopic gastrectomy for GC. Methods: A retrospective analysis of 375 patients with LAGC who received neoadjuvant therapy from 2015 to 2022 was performed. Patients were divided into NACI group (168 patients) and NAC group (207 patients) according to NAT regimen. Results: The rate of pathologic complete response (pCR, 20.2% vs. 12.6%, P=0.04) and the rate of major pathological response (MPR, 31.0% vs. 18.8%, P=0.007) in the NACI group are significantly higher than those in the NAC group, and the NACI group also had a higher rate of R0 resection (91.3% vs. 84.1%, P=0.028). The NACI group experienced a more significant decline in ypT0 (22.0% vs. 13.0%, P=0.022) and ypN0 (67.3% vs. 53.6%, P=007), but there was no difference in disease-free survival (DFS) and overall survival (OS) at 3 years between the two groups (P>0.05). Conclusions: NACI significantly improved pCR rates and R0 resection rates in patients with LAGC without increasing perioperative risk, but did not translate into short-term survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.